Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Daniel Low, PhD
Headshot of Daniel Low
Daniel Low

Description

Summary

High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastrointestinal toxicity.

The goal of the proposed trial is to investigative in a controlled, prospective manner the robustness of this outcome, and to track quality of life over a 5-year trial period.

Official Title

Prospective Phase II Study of Stereotactic Magnetic Resonance Imaging (MRI) Guided On-table Adaptive Radiation Therapy (SMART) for Patients With Borderline or Inoperable Locally Advanced Pancreatic Cancer

Details

Keywords

Pancreatic Cancer, Radiation Therapy, SBRT, Pancreatic Neoplasms, Stereotactic MRI-guided On-table Adaptive Radiation Therapy, Ablative MRIdian SMART

Eligibility

Locations

  • UCLA
    Los Angeles California 90095 United States
  • Providence Portland Cancer Center
    Portland Oregon 97213 United States

Lead Scientist at UCLA

  • Daniel Low, PhD
    Professor, Radiation Oncology, Medicine. Authored (or co-authored) 255 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Viewray Inc.
Links
Parag Parikh, MD: Improving Pancreatic Cancer Survival by using MR Guided Adaptive Radiation
ID
NCT03621644
Study Type
Interventional
Participants
Expecting 133 study participants
Last Updated